Research Ethics Board
All research at BC Cancer involving humans or material and information derived from humans must be reviewed and approved by the BC Cancer Research Ethics Board 'REB' before the project can be activated.
The REB is comprised of members who among them pool extensive experience and knowledge in scientific investigations, cancer research, the experience of cancer patients and the ethical issues raised by research involving humans.
- Chair: Dr. Karen Gelmon
- Vice-Chair: Dr Vivien Bramwell
The REB complies with the US Department of Health and Human Services (DHHS) Code of Federal Regulations 45 CFR 46.103. These regulations state that every institution engaged in human subject research supported or conducted by the DHHS must have assurance of compliance approved by the US Office for Human Research Protections (OHRP/FDA.)
Federalwide Assurance (FWA) and Institutional Review Board (IRB) assurances with OHRP/FDA have been obtained for both BC Cancer and the BC Cancer Research Ethics Board (REB). These assurances are listed here (REBs in Canada are referred to as IRBs in the US.)
- Type of Assurance: Federalwide Assurance for "BC Cancer Agency"
- Assurance Numbers: FWA00001149
- Expiry Date: October 17, 2024
- Type of Assurance: IRB Assurance for "B.C. Cancer Agency IRB #1"
- Assurance Numbers: IRB00003797
- Expiry Date: November 14, 2022
The BC Cancer Research Ethics Board is a UBC-affilated REB. UBC Office of Research Services provides regulatory oversight for all UBC affiliated REBs. Read the Assurance of Compliance Statement.
